C16orf86

Across TCGA pan-cancer cohorts, C16orf86 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C16orf86 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher C16orf86 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C16orf86 expression acts as an unfavorable survival marker.

CESC, ACC, and BLCA are the cancer types where C16orf86 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	18	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
BLCA	DFS	Median	III,IV	0.100	0.572	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C16orf86–CESC (OS)

Open the CESC breakdown →